Aspira Women’s Health (NASDAQ:AWH) Upgraded to “Hold” by StockNews.com

StockNews.com upgraded shares of Aspira Women’s Health (NASDAQ:AWH) from a sell rating to a hold rating in a research note released on Tuesday.

Separately, Alliance Global Partners dropped their price target on Aspira Women’s Health from $7.00 to $5.50 and set a buy rating on the stock in a research report on Wednesday, August 14th.

Aspira Women’s Health Stock Performance

Shares of NASDAQ AWH opened at $0.83 on Tuesday. The stock has a market cap of $13.25 million, a P/E ratio of -0.57 and a beta of 1.48. Aspira Women’s Health has a twelve month low of $0.74 and a twelve month high of $6.01. The stock has a 50 day moving average of $1.06 and a two-hundred day moving average of $2.02.

Aspira Women’s Health (NASDAQ:AWH) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.04. The business had revenue of $2.42 million during the quarter, compared to analysts’ expectations of $2.60 million. During the same quarter last year, the company earned ($0.28) EPS. As a group, research analysts predict that Aspira Women’s Health will post -1.26 earnings per share for the current year.

Institutional Trading of Aspira Women’s Health

An institutional investor recently raised its position in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. lifted its holdings in Aspira Women’s Health Inc. (NASDAQ:AWH) by 43.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 179,371 shares of the company’s stock after buying an additional 53,997 shares during the quarter. B. Riley Wealth Advisors Inc. owned 1.73% of Aspira Women’s Health worth $732,000 as of its most recent SEC filing. Institutional investors own 12.19% of the company’s stock.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.